期刊文献+

五岳抗甲丸辅助治疗Graves病的疗效及对血清IGF-I水平的影响 被引量:1

Effect of Wuyue Kangjia Pill in combination with western medicine treatment on thyroid volumes and serum insulin-like growth factor-I levels in patients with graves disease
下载PDF
导出
摘要 目的探讨五岳抗甲丸辅助治疗Graves病(以下简称GD)的疗效及作用机制。方法将58例初诊GD患者随机分为观察组与对照组各29例,两组均口服他巴唑5-15mg或丙基硫氧嘧啶50-150mg,3次/d,观察组在此基础上加服五岳抗甲丸3-5g,3次/d。两组均连续用药3个月。观察两组治疗前后甲状腺体积及血清胰岛素样生长因子-I(IGF-I)水平变化,并行相关分析。结果两组治疗后甲状腺体积均明显缩小,血清IGF-I水平均下降,但观察组下降更明显(P〈0.01)。甲状腺体积与血清IGF-I水平呈正相关(r=0.57,P〈0.01)。结论五岳抗甲丸治疗GD效果确切,其机制可能为降低血清IGF-I的水平。 Objective To study the effect of the Wuyue Kangjia Pill (WKP) in combination with medicine treatment on thyroid volumes and serum insulin-like growth factor-I (IGF-I) levels in patients with Graves disease (GD). Methods 58 patients were divided into two groups: Group A was treated with methimazole (MT) or propyhhiouracil (PTU) alone and Group B was treated with MT or PTU combined with WKP. Thyroid volumes and serum IGF-I levels in patients were al- so observed in Group A and B before and after treatment. The correlation between thyroid volumes and serum IGF-I levels in patients was analyzed. Results The two parameters in Group A and Group B were decreased after treatment (P 〈 0.05 ). They were decreased more in Group B than in Group A after treatment (all P 〈0.01 ). There was a positive correlation between thyroid volumes and serum IGF-I levels in patients ( r = 0. 57, P 〈: 0.01 ). Conclusions WKP in combination with western medicine treatment can improve goiters more effectively than only traditional western medicine by decreasing serum IGF-I levels of patients with GD.
出处 《山东医药》 CAS 北大核心 2008年第8期30-32,共3页 Shandong Medical Journal
基金 国家自然科学基金资助项目(30672048) 山东省科技厅科技攻关课题项目(2003-33) 山东省中医药管理局科研基金资助项目(2005-070)
关键词 GRAVES病 胰岛素样生长因子-I 五岳抗甲丸 Graves disease insulln-llke growth factor-I Chinese herbal medicine
  • 相关文献

参考文献7

  • 1姜玉新,张淑琴,张缙熙,周新建,刘世贞.B超测量甲状腺体积(重量)与核素显像对比研究[J].中国超声医学杂志,1997,13(4):12-14. 被引量:19
  • 2Rotman-Pikielny P, Braeker-Davls F, Tamer ML, et al. Lack of effect of long-term octreotide therapy in severe thyroid-associated dermopathy[J]. Thyroid,2003,13(5) :465-470.
  • 3T Mitsiades CS, Poulaki V, Mitsiades N, et al. Endocrine evaluation of patients with critical illness [ J]. Endocrinol Metab Clin North Am,2003,32(2) :385-410.
  • 4Kimura T, Van Keymeulen A, Golstein J, et al. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models[ J ]. Endocr Rev, 2001,22(5) :631-656.
  • 5Mitsiades CS, Poulaki V, Mitsiades N. The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer [ J]. J Endocrinol,2003,178(2) :205-216.
  • 6Poulaki V, Mitsiades CS, Mc Mullan C, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor 1 in thyroid carcinomas[ J ] . J Clin Endocrinol Metab, 2003,88 ( 11 ):5392-5398.
  • 7Mincione G, Esposito DL,Di Marcantonio MC, et al. TGF-beta 1 modulation of IGF-I signaling pathway in rat thyroid epithelial cells [ J ]. Exp Cell Res ,2003 ,287 (2) :411-423.

共引文献18

同被引文献14

  • 1Benedini S,Codella R,Caumo A.Different circulating ghre- lin responses to isoglucidic snack food in healthy individu- als[J].Horm Metab Res,2011,43(2) : 135-140.
  • 2Bossowski A, Sawicka B,Szalecki M,et al.Analysis of serum adiponectin,resistin and leptin levels in children and ado- lescents with autoimmune thyroid disorders[J].J Pediatr En- docrinol Metab, 2010,23 (4) : 369-377.
  • 3Ruchala M, Gurgul E, Stangierski A.Individual plasma ghre- lin changes in the same patients in hyperthyroid,hypothy- roid and euthyroid state[J].Peptides, 2014,51 ( 1 ) : 31-34.
  • 4Emami A,Nazem R,Hedayati M.Is association between thyroid hormones and gut peptides,ghrelin and obestatin, able to suggest new regulatory relation between the HPT axis and gut[J].Regul Pept, 2014, 189( 1 ) : 17-21.
  • 5Kumar S,Iyer S,Bauer H.A stimulatory thyrotropin recep- tor antibody enhances hyaluronic acid synthesis in Graves' orbital fibroblasts:inhibition by an IGF-I receptor block- ing antibody[J]Clin Endocrinol Metab, 2012,97 (5) : 1681 - 1687.
  • 6Smith TJ.Potential role for bone marrow-derived fibrocytes in the orbital fibroblast heterogeneity associated with thy- roid-associated ophthalmopathy[J].Clin Exp Immunol,2010, 162(1) :24-31.
  • 7卢丽娜,时立新,张巧,徐淑静,彭年春,李红,张淼.不同甲状腺功能状态血清胃促生长素水平的变化[J].中华内分泌代谢杂志,2010,26(2):132-134. 被引量:11
  • 8胡长军,崔兆辉,陆卫平.甲状腺功能减退患者治疗前后血清ghrelin水平的变化[J].南京医科大学学报(自然科学版),2010,30(11):1662-1663. 被引量:2
  • 9厉连福,黄东标,邱海鸯.甲亢和甲减患者治疗前后血清IGF-I、IL-6和IL-8检测的临床意义[J].放射免疫学杂志,2012,25(1):24-25. 被引量:6
  • 10杨金,刘子太,朱琳.小剂量^(131)I治疗124例甲状腺功能亢进的临床疗效观察[J].当代医学,2013,19(8):145-146. 被引量:13

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部